689 related articles for article (PubMed ID: 23413807)
41. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications.
Sotozono C; Ueta M; Koizumi N; Inatomi T; Shirakata Y; Ikezawa Z; Hashimoto K; Kinoshita S
Ophthalmology; 2009 Apr; 116(4):685-90. PubMed ID: 19243825
[TBL] [Abstract][Full Text] [Related]
42. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006.
Yamane Y; Aihara M; Ikezawa Z
Allergol Int; 2007 Dec; 56(4):419-25. PubMed ID: 17713361
[TBL] [Abstract][Full Text] [Related]
43. Nine years of a single referral center management of Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome).
Monteiro D; Egipto P; Barbosa J; Horta R; Amarante J; Silva P; Silva A
Cutan Ocul Toxicol; 2017 Jun; 36(2):163-168. PubMed ID: 27487073
[TBL] [Abstract][Full Text] [Related]
44. Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications.
Papay J; Yuen N; Powell G; Mockenhaupt M; Bogenrieder T
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):289-96. PubMed ID: 22139991
[TBL] [Abstract][Full Text] [Related]
45. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.
Lonjou C; Borot N; Sekula P; Ledger N; Thomas L; Halevy S; Naldi L; Bouwes-Bavinck JN; Sidoroff A; de Toma C; Schumacher M; Roujeau JC; Hovnanian A; Mockenhaupt M;
Pharmacogenet Genomics; 2008 Feb; 18(2):99-107. PubMed ID: 18192896
[TBL] [Abstract][Full Text] [Related]
46. The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: a nested matched case-control study.
Gau SS; Chao PF; Lin YJ; Chang CJ; Gau CS
J Clin Psychopharmacol; 2008 Oct; 28(5):509-17. PubMed ID: 18794645
[TBL] [Abstract][Full Text] [Related]
47. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children: 20 years study in a tertiary care hospital.
Techasatian L; Panombualert S; Uppala R; Jetsrisuparb C
World J Pediatr; 2017 Jun; 13(3):255-260. PubMed ID: 27650525
[TBL] [Abstract][Full Text] [Related]
48. High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: a retrospective study of 82 cases.
Chen J; Wang B; Zeng Y; Xu H
Eur J Dermatol; 2010; 20(6):743-7. PubMed ID: 20952352
[TBL] [Abstract][Full Text] [Related]
49. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective.
Mockenhaupt M; Kelly JP; Kaufman D; Stern RS;
J Rheumatol; 2003 Oct; 30(10):2234-40. PubMed ID: 14528522
[TBL] [Abstract][Full Text] [Related]
50. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?
Garcia-Doval I; LeCleach L; Bocquet H; Otero XL; Roujeau JC
Arch Dermatol; 2000 Mar; 136(3):323-7. PubMed ID: 10724193
[TBL] [Abstract][Full Text] [Related]
51. Early treatment with nonsucrose intravenous immunoglobulin in a burn unit reduces toxic epidermal necrolysis mortality.
Aires DJ; Fraga G; Korentager R; Richie CP; Aggarwal S; Wick J; Liu DY
J Drugs Dermatol; 2013 Jun; 12(6):679-84. PubMed ID: 23839186
[TBL] [Abstract][Full Text] [Related]
52. A 10-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia.
Loo CH; Tan WC; Khor YH; Chan LC
Med J Malaysia; 2018 Apr; 73(2):73-77. PubMed ID: 29703869
[TBL] [Abstract][Full Text] [Related]
53. Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience.
Lalosevic J; Nikolic M; Gajic-Veljic M; Skiljevic D; Medenica L
Int J Dermatol; 2015 Aug; 54(8):978-84. PubMed ID: 25385069
[TBL] [Abstract][Full Text] [Related]
54. Bullous fixed drug eruption masquerading as recurrent Stevens Johnson syndrome.
Dharamsi FM; Michener MD; Dharamsi JW
J Emerg Med; 2015 May; 48(5):551-4. PubMed ID: 25433836
[TBL] [Abstract][Full Text] [Related]
55. [Surveillance of severe cutaneous drug reactions: experience REACT-Lombardia].
Gamba C; Schroeder J; Citterio A; Cazzaniga S; Rivolta AL; Vighi G;
Recenti Prog Med; 2014 Oct; 105(10):379-84. PubMed ID: 25282350
[TBL] [Abstract][Full Text] [Related]
56. Energy requirements of pediatric patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Mayes T; Gottschlich M; Khoury J; Warner P; Kagan R
Nutr Clin Pract; 2008; 23(5):547-50. PubMed ID: 18849560
[TBL] [Abstract][Full Text] [Related]
57. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis.
Caproni M; Torchia D; Schincaglia E; Volpi W; Frezzolini A; Schena D; Marzano A; Quaglino P; De Simone C; Parodi A; Barletta E; Fabbri P
Br J Dermatol; 2006 Oct; 155(4):722-8. PubMed ID: 16965421
[TBL] [Abstract][Full Text] [Related]
58. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain.
Kulkantrakorn K; Tassaneeyakul W; Tiamkao S; Jantararoungtong T; Prabmechai N; Vannaprasaht S; Chumworathayi P; Chen P; Sritipsukho P
Pain Pract; 2012 Mar; 12(3):202-8. PubMed ID: 21676164
[TBL] [Abstract][Full Text] [Related]
59. Stevens-johnson Syndrome and Toxic Epidermal Necrolysis: An Overview of Diagnosis, Therapy Options and Prognosis of Patients.
Garg VK; Buttar HS; Bhat SA; Ainur N; Priya T; Kashyap D; Tuli HS
Recent Adv Inflamm Allergy Drug Discov; 2023; 17(2):110-120. PubMed ID: 37605396
[TBL] [Abstract][Full Text] [Related]
60. Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis.
Tang YH; Mockenhaupt M; Henry A; Bounoua M; Naldi L; Le Gouvello S; Bensussan A; Roujeau JC
Clin Exp Allergy; 2012 Feb; 42(2):248-54. PubMed ID: 22092454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
